Obesity and breast cancer – what’s new?

References

• Arnold M, Pandeya N, Byrnes G, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2015;16(1):36–46.
   PubMed Web of Science ®Google Scholar
• Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: a systematic review and meta-analysis. Ann Int Med. 2013;159(11):758–769.
   PubMed Web of Science ®Google Scholar
• Heo M, Kabat GC, Strickler HD, et al. Optimal cutoffs of obesity measures in relation to cancer risk in postmenopausal women in the women’s health initiative study. J Womens Health (Larchmt). 2015;24(3):218–227.
   PubMed Web of Science ®Google Scholar
• Cheraghi Z, Poorolajal J, Hashem T, et al. Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: a meta-analysis. PLoS One. 2012;7(12):e51446.
   PubMed Web of Science ®Google Scholar
• Munsell MF, Sprague BL, Berry DA, et al. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol Rev. 2014;36:114–136.
   PubMed Web of Science ®Google Scholar
• Xia X, Chen W, Li J, et al. Body mass index and risk of breast cancer: a nonlinear dose-response meta-analysis of prospective studies. Sci Rep. 2014;4:7480.
   PubMed Web of Science ®Google Scholar
• Neuhouser ML, Aragaki AK, Prentice RL, et al. Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the women’s health initiative randomized clinical trials. JAMA Oncol. 2015;1(5):611–621.
   PubMed Web of Science ®Google Scholar
• Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;137(1):307–314.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Folkerd E. Reduced progesterone levels explain the reduced risk of breast cancer in obese premenopausal women: a new hypothesis. Breast Cancer Res Treat. 2015;149(1):1–4.
   PubMed Web of Science ®Google Scholar
• Hvidtfeldt UA, Gunter MJ, Lange T, et al. Quantifying mediating effects of endogenous estrogen and insulin in the relation between obesity, alcohol consumption, and breast cancer. Cancer Epidemiol Biomarkers Prev. 2012;21(7):1203–1212.
   PubMed Web of Science ®Google Scholar
• Kwan ML, Kroenke CH, Sweeney C, et al. Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression. BMC Cancer. 2015;15:278.
   PubMed Web of Science ®Google Scholar
• Toro AL, Costantino NS, Shriver CD, et al. Effect of obesity on molecular characteristics of invasive breast tumors: gene expression analysis in a large cohort of female patients. BMC Obesity. 2016;3:22.
   PubMedGoogle Scholar
• Fuentes-Mattei E, Velazquez-Torres G, Phan L, et al. Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer. J Natl Cancer Inst. 2014;106(7):pii:dju158.
   PubMedGoogle Scholar
• Creighton CJ, Sada YH, Zhang Y, et al. A gene transcription signature of obesity in breast cancer. Breast Cancer Res Treat. 2012;132(3):993–1000.
   PubMed Web of Science ®Google Scholar
• Atkinson RL, El-Zein R, Valero V, et al. Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes Control. 2016;27(3):359–366.
   PubMed Web of Science ®Google Scholar
• Abe R, Kumagai N, Kimura M, et al. Biological characteristics of breast cancer in obesity. Tohoku J Exp Med. 1976;120(4):351–359.
   PubMed Web of Science ®Google Scholar
• Chan DS, Vieira AR, Aune D, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014;25(10):1901–1914.
   PubMed Web of Science ®Google Scholar
• Ewertz M, Jensen MB, Gunnarsdottir KA, et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol. 2011;29(1):25–31.
   PubMed Web of Science ®Google Scholar
• Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer ResTreat. 2010;123(3):627–635.
   PubMed Web of Science ®Google Scholar
• Niraula S, Ocana A, Ennis M, et al. Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. Breast Cancer ResTreat. 2012;134(2):769–781.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Wang M, Zhao F, et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer. 2012;118(23):5937–5946.
   PubMed Web of Science ®Google Scholar
• Pajares B, Pollan M, Martin M, et al. Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. Breast Cancer Res. 2013;15(6):R105.
   PubMed Web of Science ®Google Scholar
• Sestak I, Distler W, Forbes JF, et al. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol. 2010;28(21):3411–3415.
   PubMed Web of Science ®Google Scholar
• Pfeiler G, Konigsberg R, Fesl C, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol. 2011;29(19):2653–2659.
   PubMed Web of Science ®Google Scholar
• Gnant M, Pfeiler G, Stoger H, et al. The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. Br J Cancer. 2013;109(3):589–596.
   PubMed Web of Science ®Google Scholar
• Ewertz M, Gray KP, Regan MM, et al. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol. 2012;30(32):3967–3975.
   PubMed Web of Science ®Google Scholar
• Hankinson SE, Willett WC, Manson JE, et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst. 1995;87(17):1297–1302.
   PubMedGoogle Scholar
• Rock CL, Flatt SW, Laughlin GA, et al. Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(3):614–620.
   PubMed Web of Science ®Google Scholar
• Strong AL, Burow ME, Gimble JM, et al. Concise review: The obesity cancer paradigm: exploration of the interactions and crosstalk with adipose stem cells. Stem Cells. 2015;33(2):318–326.
   PubMed Web of Science ®Google Scholar
• Rose DP, Gracheck PJ, The V-DL. Interactions of obesity, inflammation and insulin resistance in breast cancer. Cancers (Basel). 2015;7(4):2147–2168.
   PubMedGoogle Scholar
• Orecchioni S, Reggiani F, Talarico G, et al. Mechanisms of obesity in the development of breast cancer. Discov Med. 2015;20(109):121–128.
   PubMed Web of Science ®Google Scholar
• Simone V, D’Avenia M, Argentiero A, et al. Obesity and breast cancer: molecular interconnections and potential clinical applications. Oncologist. 2016;21(4):404–417.
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Stambolic V. Impact of the obesity epidemic on cancer. Ann Rev Med. 2015;66:281–296.
   PubMed Web of Science ®Google Scholar
• Harvie M, Howell A, Vierkant RA, et al. Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women’s health study. Cancer Epidemiol Biomarkers Prev. 2005;14(3):656–661.
   PubMed Web of Science ®Google Scholar
• Adams TD, Stroup AM, Gress RE, et al. Cancer incidence and mortality after gastric bypass surgery. Obesity (Silver Spring). 2009;17(4):796–802.
   PubMed Web of Science ®Google Scholar
• Del Giudice ME, Fantus IG, Ezzat S, et al. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat. 1998;47(2):111–120.
   PubMed Web of Science ®Google Scholar
• Autier P, Koechlin A, Boniol M, et al. Serum insulin and C-peptide concentration and breast cancer: a meta-analysis. Cancer Causes Control. 2013;24(5):873–883.
   PubMed Web of Science ®Google Scholar
• Esposito K, Chiodini P, Capuano A, et al. Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis. Menopause. 2013;20(12):1301–1309.
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002;20(1):42–51.
   PubMed Web of Science ®Google Scholar
• Pritchard KI, Shepherd LE, Chapman JA, et al. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. J Clin Oncol. 2011;29(29):3869–3876.
   PubMed Web of Science ®Google Scholar
• Irwin ML, Duggan C, Wang CY, et al. Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. J Clin Oncol. 2011;29(1):47–53.
   PubMed Web of Science ®Google Scholar
• Duggan C, Irwin ML, Xiao L, et al. Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol. 2011;29(1):32–39.
   PubMed Web of Science ®Google Scholar
• Law JH, Habibi G, Hu K, et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 2008;68(24):10238–10246.
   PubMed Web of Science ®Google Scholar
• Seshasai SR, Kaptoge S, Thompson A, et al.; Emerging Risk Factors C. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829–841.
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Ennis M, Pritchard KI, et al. Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. J Clin Oncol. 2012;30(2):164–171.
   PubMed Web of Science ®Google Scholar
• Macis D, Guerrieri-Gonzaga A, Gandini S. Circulating adiponectin and breast cancer risk: a systematic review and meta-analysis. Int J Epidemiol. 2014;43(4):1226–1236.
   PubMed Web of Science ®Google Scholar
• Niu J, Jiang L, Guo W, et al. The association between leptin level and breast cancer: a meta-analysis. PLoS One. 2013;8(6):e67349.
   PubMed Web of Science ®Google Scholar
• Touvier M, Fassier P, His M, et al. Cholesterol and breast cancer risk: a systematic review and meta-analysis of prospective studies. Br J Nutr. 2015;114(3):347–357.
   PubMed Web of Science ®Google Scholar
• Bahl M, Ennis M, Tannock IF, et al. Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort study. Breast Cancer Res Treat. 2005;94(2):135–144.
   PubMed Web of Science ®Google Scholar
• Morris PG, Hudis CA, Giri D, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila). 2011;4(7):1021–1029.
   PubMed Web of Science ®Google Scholar
• Howe LR, Subbaramaiah K, Hudis CA, et al. Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin Cancer Res. 2013;19(22):6074–6083.
   PubMed Web of Science ®Google Scholar
• Iyengar NM, Zhou XK, Gucalp A, et al. Systemic correlates of white adipose tissue inflammation in early-stage breast cancer. Clin Cancer Res. 2016;22(9):2283–2289.
   PubMed Web of Science ®Google Scholar
• Chang MC, Eslami Z, Ennis M, et al. Prevalence of crown-like structures of the breast, a histologic biomarker linked to obesity: a retrospective study of 99 cases. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8–12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-05-01.
   Google Scholar
• Chan DS, Bandera EV, Greenwood DC, et al. Circulating C-reactive protein and breast cancer risk-systematic literature review and meta-analysis of prospective cohort studies. Cancer Epidemiol Biomarkers Prev. 2015;24(10):1439–1449.
   PubMed Web of Science ®Google Scholar
• Tibau A, Ennis M, Goodwin PJ. Post-surgical highly sensitive C-reactive protein and prognosis in early-stage breast cancer. Breast Cancer Res Treat. 2013;141(3):485–493.
   PubMed Web of Science ®Google Scholar
• Eliassen AH, Colditz GA, Rosner B, et al. Adult weight change and risk of postmenopausal breast cancer. JAMA. 2006;296(2):193–201.
   PubMed Web of Science ®Google Scholar
• Parker ED, Folsom AR. Intentional weight loss and incidence of obesity-related cancers: the Iowa women’s health study. Int J Obes Relat Metab Disord. 2003;27(12):1447–1452.
   PubMed Web of Science ®Google Scholar
• Christou NV, Lieberman M, Sampalis F, et al. Bariatric surgery reduces cancer risk in morbidly obese patients. Surg Obes Relat Dis. 2008;4(6):691–695.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Blackburn GL, Thomson CA, et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the women’s intervention nutrition Study. J Natl Cancer Inst. 2006;98(24):1767–1776.
   PubMed Web of Science ®Google Scholar
• Pierce JP, Natarajan L, Caan BJ, et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women’s Healthy Eating and Living (WHEL) randomized trial. JAMA. 2007;298(3):289–298.
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Stambolic V, Lemieux J, et al. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat. 2011;126(1):215–220.
   PubMed Web of Science ®Google Scholar
• DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–271.
   PubMed Web of Science ®Google Scholar